CN109481422A - A kind of graphene oxide Electric radiant Heating Film transdermal patch - Google Patents
A kind of graphene oxide Electric radiant Heating Film transdermal patch Download PDFInfo
- Publication number
- CN109481422A CN109481422A CN201811387114.0A CN201811387114A CN109481422A CN 109481422 A CN109481422 A CN 109481422A CN 201811387114 A CN201811387114 A CN 201811387114A CN 109481422 A CN109481422 A CN 109481422A
- Authority
- CN
- China
- Prior art keywords
- graphene oxide
- radiant heating
- electric radiant
- heating film
- transdermal patch
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M2037/0007—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin having means for enhancing the permeation of substances through the epidermis, e.g. using suction or depression, electric or magnetic fields, sound waves or chemical agents
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Medical Informatics (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention discloses a kind of graphene oxide Electric radiant Heating Film transdermal patch, and the graphene oxide Electric radiant Heating Film transdermal patch successively includes: graphene oxide Electric radiant Heating Film, backing film, drug-reservoir and protective film from top to bottom.Graphene oxide Electric radiant Heating Film transdermal patch of the present invention can make patch maintain the certain temperature higher than body temperature relative to traditional patch, and the lipid structure of skin is made to change, and promote drugs through skin, improve therapeutic effect；Skin surface maintains set temperature for a long time, and relaxing tendons and activating collaterals promotes blood circulation, is conducive to relieve pain, and therapeutic effect is significant, has snugness, improves the drug compliance of patient.In addition, graphene oxide Electric radiant Heating Film transdermal patch controllably quantity of heat given up and accurately can adjust temperature, realize long lasting for stable heating, to keep dosage more accurate；It is bonded using dismountable mode, it can be achieved that interrupting heat supply and Electric radiant Heating Film recycling in time.
Description
Technical field
The present invention relates to pharmaceutical technology fields.More particularly, to a kind of graphene oxide Electric radiant Heating Film transdermal patch.
Background technique
Percutaneous dosing technology has many advantages compared with traditional administration mode, avoids liver to " the first mistake of drug
The decomposition of effect " and gastrointestinal tract improves therapeutic effect；The blood concentration to keep relative stability avoids peak valley phenomenon, reduces secondary make
With；Extend administration time, reduces administration number of times, improve the compliance of patient.These unique advantages have attracted numerous pharmacy works
Industry department researches and develops new percutaneous preparation.
Since skin plays barrier action, the especially cutin of skin outermost layer " brick wall structure " to the absorption of drug percutaneous
Layer.While protecting body not invaded and harassed by allogenic material, all play the role of rate limiting barrier to any drug molecule.In order to increase
The transdermal penetration amount of dosing object, the various new methods for enhancing transdermal delivery continue to bring out.The use of chemical skin reinforcing agent can increase
The passive transdermal penetration for adding small-molecule drug, can not overcome the size limiting factor of macromolecular drug.Penetration enhancer it is another
A drawbacks common is to increase the percutaneous of drug by interfering orderly cuticula lipid bilayer or horn cell structure due to them
Permeability easily causes skin allergy.
Physical enhancement technology using with improve percutaneous penetration of drugs by the way of combination of devices, such as promote by outside energy
Active medicine-feeding technology into drug permeability includes pressure-driven jet stream, iontophoresis dermal patch, micropin, laser and heating etc.
Mode.Great impetus is played in terms of widening the medicament categories suitable for percutaneous dosing field.
The achievement obtained in terms of material science and nanotechnology promotes the exploitation of the various materials as pharmaceutical carrier.It is special
It is not graphene-based material due to its high load capability, is started using outside stimulus such as pH, electricity, electrochemistry, light graphene-based
Drug release in matter causes great concern in the field.For needing the drug of release for a long time, it is one that heating, which promotees to seep,
The effective method of kind.Graphene oxide makes it in heat conduction and heat radiation material, electric heating film, catalyst carrier etc. with its excellent performance
There is good application prospect in field, also higher and higher in the attention rate of field of medicine release.In graphene oxide as drug
It is found in the research of carrier, it is maximally efficient one of mode that the electrocaloric effect by being electrically excited generation, which drives the release of drug,.
Thermal control drug delivery system is usually by the drug release of heat triggering carrier.The percutaneous of drug can be controlled by hot activation patch
Infiltration rate, this provides solution for the release of long-term control active constituent.
Traditional thermotherapy method usually heats the carriers such as deposited, the heat accumulation gel of volcanic mud in advance, stores up body as latent heat, or
Person discharges heat by the oxidation process of iron powder.Additionally the substances such as capsaicine can be added in patch to stimulate skin, with
Generate subjective thermal sensation.
However, the common disadvantage of the above method be can not controllably heat supply, cannot accurate adjustment effect temperature, also not
It is able to achieve long lasting for stable heating.And pyrogen is integrated into patch, is not removed from patient skin
The patch just can not interrupt heat supply.
Summary of the invention
The purpose of the present invention is to provide a kind of graphene oxide Electric radiant Heating Film transdermal patches, by being electrically excited graphene oxide
The electrocaloric effect controllably quantity of heat given up that film generates, promotes the release of drug, improves the transdermal penetration amount of drug, has good
Good therapeutic effect.
In order to achieve the above objectives, the present invention adopts the following technical solutions:
The present invention provides a kind of graphene oxide Electric radiant Heating Film transdermal patches, from top to bottom successively include: graphene oxide
Electric radiant Heating Film, backing film, drug-reservoir and protective film.
Further, the graphene oxide Electric radiant Heating Film is heated by being connected to power supply, and operative temperature is 35-50 DEG C, excellent
Choosing is 40-45 DEG C.
Further, the graphene oxide Electric radiant Heating Film is removably bonded on backing film, can preferably pass through heat-resistant adhesive
Water bonding.
Further, the graphene oxide Electric radiant Heating Film includes graphene oxide conductive layer and insulating protective layer.
Further, the material of the insulating protective layer be polyimides, it is a kind of in polyethylene terephthalate or two
The mixture of kind, resistance are 2-20 Ω.
Further, the drug-reservoir is hydrogel adhesive or pressure-sensitive adhesive.
Further, the raw material of the hydrogel adhesive includes bulk pharmaceutical chemicals, high-molecular bone frame material, moisturizer, sticky agent, filling
Agent.When the preparation method for the graphene oxide Electric radiant Heating Film transdermal patch that drug-reservoir is hydrogel adhesive is general are as follows: mix each raw material
It is added to the water after conjunction and is stirred dispersion, stand removing bubble and obtain ointment, ointment is coated on protective layer with certain thickness
On, coating thickness 0.1-2mm, preferred thickness is that 0.3-1mm covers backing film, is compressed, and being cut into areal extent is 5-
100cm2Patch, on backing film be bonded graphene oxide Electric radiant Heating Film to get.
Preferably, the high-molecular bone frame material includes but is not limited to acrylate, polyvinyl alcohol, gelatin, polyacrylic acid
Sodium, cellulose derivative, chitosan derivatives, acid polyethylene pyrrolidones, mixture one or more in the sub- glue of sand sagebrush (Artemisia filifolia)；Institute
Stating sticky agent includes but is not limited to polyacrylic acid and its sodium salt.Moisturizer includes: glycerol, propylene glycol, a kind of or more in sorbierite
The mixture of kind；The filler include but is not limited to superfine silica gel powder, calcium carbonate, kaolin, bentonite, titanium dioxide, zinc oxide,
One or more mixture in talcum powder.
Further, the raw material of the pressure-sensitive adhesive includes bulk pharmaceutical chemicals, pressure sensitive adhesive and solubilizer.When drug-reservoir is pressure-sensitive
The preparation method of the graphene oxide Electric radiant Heating Film transdermal patch of adhesive is general are as follows: is added in pressure sensitive adhesive after mixing each raw material
It is uniformly mixed, stands 1 hour removing bubble, obtain drug containing glue；Drug containing glue is coated on protective layer with certain thickness
On, coating thickness is 300-600 μm, 70-90 DEG C of dry 10-20min, and covering backing film is taken out after drying, compresses, is cut into face
Product range is 5-100cm2Patch, on backing film be bonded graphene oxide Electric radiant Heating Film to get.
Preferably, the pressure sensitive adhesive selects pressure-sensitive acrylate or polyisobutene class pressure-sensitive according to the property of bulk pharmaceutical chemicals
Glue；The solubilizer includes but is not limited to lactic acid, sodium lactate, boric acid, citric acid, mixture one or more of in tartaric acid.
Further, the bulk pharmaceutical chemicals can be cosmetic actives and drug effective component, pressure-sensitive adhesive and water-setting
Bulk pharmaceutical chemicals described in jelly are selected according to the property of bulk pharmaceutical chemicals, are specifically including but not limited to analgesic active principle, fat reducing has
Imitate mixture one or more of in ingredient, scar of dispelling effective component, whitening effective component, rheumatism and antirheumatic.Preferably,
The analgesic active principle include but is not limited to paracetamol, non-steroidal anti-inflammatory drugs (such as: brufen, naproxen, A Si
Woods, fenoprofen, Flurbiprofen, Ketoprofen, olsapozine (oxaprozin), C14H10Cl2NNaO2, Etodolac, indoles beauty
Pungent ketorolac, sulindac MCN 2559 Meclofenamate/ester, mefenamic acid, Nabumetone piroxicam and cox 2 inhibitor etc.),
Corticosteroid (such as: cortisone), anesthetic, anticonvulsant (such as Gabapentin, Pregabalin), local anesthetic (example
Such as: bagodryl hydrochloride, chlorphenamine maleate antihistaminic；The anesthetic such as yellow Jackets) etc.；The fat reducing effectively at
Divide includes but is not limited to L-carnitine, orlistat, dimethylbiguanide；Scar of dispelling effective component include but is not limited to acetic acid Qu An how
Moral, pheretima polypeptide, carnosine, asiaticosid, hirudin, ginsenoside；The whitening effective component includes but is not limited to Vitamin C
Acid, magnesium ascorbyl phosphate, tranexamic acid, ascorbic acid glucoside (ascorbylglucoside), ascorbyl palmitate,
Licorice, yeast extract, Trametes (trametes), aspergillus (aspergillus), Exophiala
(exophilia), resveratrol and derivative resveratrol phosphate, resveratrol ferulate, oxidized resveratrol, asafoetide
Acid and its derivative, azelaic acid, azelaic acid derivant, kojic acid, ellagic acid, chamenol, extract of soybean, Scutellaria baicalensis extract, mulberry
Shen extract, molasses, tetrahydro curcumin, enoxolone, smart niacinamide, pomegranate, grape seed extract, prestige compose hops, BV-
Tetra- hexyl decyl alcohol acid ascorbyl ester of OSC-, ascorbic acid disodium hydrogen phosphate, ascorbic acid glucoside, α (β)-arbutin, Vitamin C
Sour palmitate, resorcinol and Trenaxmine；The rheumatism and antirheumatic include but is not limited to C14H10Cl2NNaO2, double chlorine sweet smell
Diethylammonium salt, marasmius androsaceus, spantol, safflower extract, Sanguis Draxonis extract, Radix Clematidis extract, Herba Lycopodii extract etc.；It is described
Crease-resistant effective component includes but is not limited to sheep placenta, retinol, retinyl acetate, Retinol Palmitate, vitamin A acid, dimension
Raw element A acetic acid esters vitamin C and its derivative.
Preferably, the content range of bulk pharmaceutical chemicals is 0.2-2mg in graphene oxide Electric radiant Heating Film transdermal patch every square centimeter.
Further, the backing film be one or more layers laminated film, material include polyethylene terephthalate,
Polypropylene, polyethylene, vinyl-vinyl acetate copolymer, mixture one or more in polyurethane.
Further, the backing film with a thickness of 30-300 μm.
Further, the material of the protective film is surface by plasma treatment, painting fluorine or applies the poly- to benzene two of silicon processing
Formic acid glycol ester, polyethylene, mixture one or more in polypropylene film, the preferably poly- terephthaldehyde of painting fluorine processing
Sour glycol ester.
Further, the protective film with a thickness of 20-300 μm.
Beneficial effects of the present invention are as follows:
1, graphene oxide Electric radiant Heating Film transdermal patch of the present invention can be such that patch maintains higher than body relative to traditional patch
The certain temperature of temperature, makes the lipid structure of skin change, and promotes drugs through skin, improves therapeutic effect；Skin surface
Set temperature is maintained for a long time, and relaxing tendons and activating collaterals promotes blood circulation, is conducive to relieve pain, and therapeutic effect is significant, has warm
Comfort improves the drug compliance of patient.
2, graphene oxide Electric radiant Heating Film transdermal patch of the present invention controllably quantity of heat given up and accurately can adjust temperature, realize
Long lasting for stable heating, to keep dosage more accurate.
3, graphene oxide Electric radiant Heating Film transdermal patch of the present invention is bonded, it can be achieved that cut-off in time using dismountable mode
Heat and Electric radiant Heating Film recycling.
Detailed description of the invention
Specific embodiments of the present invention will be described in further detail with reference to the accompanying drawing.
Fig. 1 shows the side structure schematic view of graphene oxide Electric radiant Heating Film percutaneous plaster of the present invention；Wherein 1- is aoxidized
Graphene Electric radiant Heating Film, 2- backing film, 3- drug-reservoir, 4- protective film.
Fig. 2 shows 3.5mm circle graphene oxide Electric radiant Heating Films: A, graphene oxide Electric radiant Heating Film pictorial diagram；B, graphite oxide
Alkene electric-heating membrane imager figure.
Fig. 3 shows embodiment 1 and is formulated patch cumulative release amount (absolute value) for 24 hours: a, attaching 45 DEG C of Electric radiant Heating Film；B, electricity is attached
40 DEG C of hotting mask heating；C, 50 DEG C of Electric radiant Heating Film heating are attached；D, Electric radiant Heating Film is not attached.
Fig. 4 shows the relationship that graphene oxide Electric radiant Heating Film is attached at skin surface detection temperature and voltage, resistance.
Fig. 5 shows histopathology slide after graphene oxide Electric radiant Heating Film is attached at human skin surface's heating and observes: A,
Normal skin；B, it acts on for 24 hours for 40 DEG C of graphene oxide Electric radiant Heating Film；C, it acts on for 24 hours for 45 DEG C of graphene oxide Electric radiant Heating Film；D, stone is aoxidized
50 DEG C of black alkene Electric radiant Heating Film effects are for 24 hours.
Specific embodiment
In order to illustrate more clearly of the present invention, the present invention is done further below with reference to preferred embodiments and drawings
It is bright.Similar component is indicated in attached drawing with identical appended drawing reference.It will be appreciated by those skilled in the art that institute is specific below
The content of description is illustrative and be not restrictive, and should not be limited the scope of the invention with this.
The present invention provides a kind of graphene oxide Electric radiant Heating Film transdermal patches, from top to bottom successively include: graphene oxide
Electric radiant Heating Film, backing film, drug-reservoir and protective film.
Further, the graphene oxide Electric radiant Heating Film is heated by being connected to power supply, and operative temperature is 35-50 DEG C, excellent
Choosing is 40-45 DEG C, such as can be 35 DEG C, 40 DEG C, 45 DEG C, 50 DEG C etc..The present invention passes through controllably quantity of heat given up and essence
Quasi- adjusting temperature is realized long lasting for stable heating, to keep dosage more accurate.
Further, the graphene oxide Electric radiant Heating Film is removably bonded on backing film, can preferably pass through heat-resistant adhesive
Water bonding.Tear protective layer when use off, drug-reservoir is pasted on skin, and connection power supply graphene oxide Electric radiant Heating Film remains suitable
Temperature, promote drugs through skin, enhancing therapeutic effect, it can be achieved that in time interrupt heat supply and Electric radiant Heating Film recycling.
Further, the graphene oxide Electric radiant Heating Film includes graphene oxide conductive layer and insulating protective layer.
Further, the material of the insulating protective layer be polyimides, it is a kind of in polyethylene terephthalate or two
The mixture of kind, resistance are 2-20 Ω.
Further, the drug-reservoir is hydrogel adhesive or pressure-sensitive adhesive.
Further, the raw material of the hydrogel adhesive includes bulk pharmaceutical chemicals, high-molecular bone frame material, moisturizer, sticky agent, filling
Agent.When the preparation method for the graphene oxide Electric radiant Heating Film transdermal patch that drug-reservoir is hydrogel adhesive is general are as follows: mix each raw material
It is added to the water after conjunction and is stirred dispersion, stand removing bubble and obtain ointment, ointment is coated on protective layer with certain thickness
On, coating thickness 0.1-2mm, preferred thickness is that 0.3-1mm covers backing film, is compressed, and being cut into areal extent is 5-
100cm2Patch, on backing film be bonded graphene oxide Electric radiant Heating Film to get.
Preferably, the high-molecular bone frame material includes but is not limited to acrylate, polyvinyl alcohol, gelatin, polyacrylic acid
Sodium, cellulose derivative, chitosan derivatives, acid polyethylene pyrrolidones, mixture one or more in the sub- glue of sand sagebrush (Artemisia filifolia)；Institute
Stating sticky agent includes but is not limited to polyacrylic acid and its sodium salt.Moisturizer includes: glycerol, propylene glycol, a kind of or more in sorbierite
The mixture of kind；The filler include but is not limited to superfine silica gel powder, calcium carbonate, kaolin, bentonite, titanium dioxide, zinc oxide,
One or more mixture in talcum powder.
Further, the raw material of the pressure-sensitive adhesive includes bulk pharmaceutical chemicals, pressure sensitive adhesive and solubilizer.When drug-reservoir is pressure-sensitive
The preparation method of the graphene oxide Electric radiant Heating Film transdermal patch of adhesive is general are as follows: is added in pressure sensitive adhesive after mixing each raw material
It is uniformly mixed, stands 1 hour removing bubble, obtain drug containing glue；Drug containing glue is coated on protective layer with certain thickness
On, coating thickness is 300-600 μm, 70-90 DEG C of dry 10-20min, and covering backing film is taken out after drying, compresses, is cut into face
Product range is 5-100cm2Patch, on backing film be bonded graphene oxide Electric radiant Heating Film to get.
Preferably, the pressure sensitive adhesive selects pressure-sensitive acrylate or polyisobutene class pressure-sensitive according to the property of bulk pharmaceutical chemicals
Glue；The solubilizer includes but is not limited to lactic acid, sodium lactate, boric acid, citric acid, mixture one or more of in tartaric acid.
Solubilizer of the present invention can effectively increase solubility of the bulk pharmaceutical chemicals in pressure sensitive adhesive.
Further, the bulk pharmaceutical chemicals can be cosmetic actives and drug effective component, pressure-sensitive adhesive and water-setting
Bulk pharmaceutical chemicals described in jelly are selected according to the property of bulk pharmaceutical chemicals, are specifically including but not limited to analgesic active principle, fat reducing has
Imitate mixture one or more of in ingredient, scar of dispelling effective component, whitening effective component, rheumatism and antirheumatic.Preferably,
The analgesic active principle include but is not limited to paracetamol, non-steroidal anti-inflammatory drugs (such as: brufen, naproxen, A Si
Woods, fenoprofen, Flurbiprofen, Ketoprofen, olsapozine (oxaprozin), C14H10Cl2NNaO2, Etodolac, indoles beauty
Pungent ketorolac, sulindac MCN 2559 Meclofenamate/ester, mefenamic acid, Nabumetone piroxicam and cox 2 inhibitor etc.),
Corticosteroid (such as: cortisone), anesthetic, anticonvulsant (such as Gabapentin, Pregabalin), local anesthetic (example
Such as: bagodryl hydrochloride, chlorphenamine maleate antihistaminic；The anesthetic such as yellow Jackets) etc.；The fat reducing effectively at
Divide includes but is not limited to L-carnitine, orlistat, dimethylbiguanide；Scar of dispelling effective component include but is not limited to acetic acid Qu An how
Moral, pheretima polypeptide, carnosine, asiaticosid, hirudin, ginsenoside；The whitening effective component includes but is not limited to Vitamin C
Acid, magnesium ascorbyl phosphate, tranexamic acid, ascorbic acid glucoside (ascorbylglucoside), ascorbyl palmitate,
Licorice, yeast extract, Trametes (trametes), aspergillus (aspergillus), Exophiala
(exophilia), resveratrol and derivative resveratrol phosphate, resveratrol ferulate, oxidized resveratrol, asafoetide
Acid and its derivative, azelaic acid, azelaic acid derivant, kojic acid, ellagic acid, chamenol, extract of soybean, Scutellaria baicalensis extract, mulberry
Shen extract, molasses, tetrahydro curcumin, enoxolone, smart niacinamide, pomegranate, grape seed extract, prestige compose hops, BV-
Tetra- hexyl decyl alcohol acid ascorbyl ester of OSC-, ascorbic acid disodium hydrogen phosphate, ascorbic acid glucoside, α (β)-arbutin, Vitamin C
Sour palmitate, resorcinol and Trenaxmine；The rheumatism and antirheumatic include but is not limited to C14H10Cl2NNaO2, double chlorine sweet smell
Diethylammonium salt, marasmius androsaceus, spantol, safflower extract, Sanguis Draxonis extract, Radix Clematidis extract, Herba Lycopodii extract etc.；It is described
Crease-resistant effective component includes but is not limited to sheep placenta, retinol, retinyl acetate, Retinol Palmitate, vitamin A acid, dimension
Raw element A acetic acid esters vitamin C and its derivative.
Preferably, the content range of bulk pharmaceutical chemicals is 0.2-2mg in graphene oxide Electric radiant Heating Film transdermal patch every square centimeter.
It such as can be 0.2mg, 0.5mg, 1mg, 1.5mg, 2mg etc..
Further, the backing film be one or more layers laminated film, material include polyethylene terephthalate,
Polypropylene, polyethylene, vinyl-vinyl acetate copolymer, mixture one or more in polyurethane.
Further, the backing film with a thickness of 30-300 μm.It such as can be 30 μm, 50 μm, 100 μm, 150 μm, 200
μm, 250 μm, 300 μm etc..
Further, the material of the protective film is surface by plasma treatment, painting fluorine or applies the poly- to benzene two of silicon processing
Formic acid glycol ester, polyethylene, mixture one or more in polypropylene film, the preferably poly- terephthaldehyde of painting fluorine processing
Sour glycol ester.
Further, the protective film with a thickness of 20-300 μm.It such as can be 20 μm, 50 μm, 100 μm, 150 μm, 200
μm, 250 μm, 300 μm etc..
Hereinafter the present invention will be further described through by specific embodiment.
In the present invention, if not refering in particular to, used raw material and equipment etc. are commercially available or commonly used in the art.
Method in following embodiments is unless otherwise instructed the conventional method of this field.
1 C14H10Cl2NNaO2 transdermal patch for relieving pain of embodiment
1, drug-reservoir formula:
2, prepared by patch
C14H10Cl2NNaO2 is added in ethyl alcohol, lactic acid is added after mixing, dissolves C14H10Cl2NNaO2, DURO-TAK is added
87-2677 medical pressure sensitive adhesive (contains acrylate and vinyl acetate copolymer 39.5%, ethyl acetate 22.4%, isopropanol
22.4%, heptane 12.7%, toluene 3%), 60 DEG C temperature constant magnetic stirring 1 hour, stand 1 hour removing bubble, be coated on protection
On film, coating thickness is 300 μm, 70 DEG C of drying 20min, covers backing film, is compressed, cutting, the bonding oxidation stone on backing film
Black alkene Electric radiant Heating Film, aluminium plastic bag are sealed.
Protective film is torn when use, drug-reservoir layer is pasted on skin, and graphene oxide Electric radiant Heating Film connection power supply adds
Heat, after, it is reusable to remove graphene oxide Electric radiant Heating Film.
Percutaneous penetration of the graphene oxide Electric radiant Heating Film transdermal patch through pig ear skin that the present embodiment is obtained: it uses
Pig ear skin is fixed on diffusion cell by improved Franz diffusing cells method, and corium is towards receiving chamber, and stratum corneum side is to supply chamber.Patch
Stratum corneum side is sticked on, appropriate pH=7.4 phosphate buffer, 37 DEG C of water bath with thermostatic control circulations and magnetic agitation are added in receiving chamber
1, it samples within 2,3,4,5,6,8,10,12,24 hours, measures sample concentration with high performance liquid chromatography, as a result see Fig. 3, it can from figure
Utilize graphene oxide heated by electrothermal film that there is apparent mechanism to find out.Graphene oxide Electric radiant Heating Film is attached at skin
Surface, the two poles of the earth connect D.C. regulated power supply output end, measure temperature and the relationship of voltage, resistance is as shown in Figure 4.0-2.5V's
In voltage range, Electric radiant Heating Film highest can make skin surface maintain 48 DEG C.It is dyed and is observed by tissue paraffin section de HE, as a result as schemed
Shown in 5, it can be seen that normal skin cuticula and epidermis are complete, no breakage, and muscle fibre is abundant, 40 DEG C and 45 DEG C heating
So that the cuticula of skin becomes loose, facilitate Medicated Permeation by skin, transdermal penetration amount highest at 45 DEG C can make patch
Percutaneous permeation improve 4.2 times, Stratum Corneums are understood in 50 DEG C of heating certain destruction.
2 L-carnitine fat reducing transdermal patch of embodiment
1. drug-reservoir formula:
2. prepared by patch:
Sodium carboxymethylcellulose, Artemisia Glue, glycerol, superfine silica gel powder, kaolin are added to the water, are uniformly mixed.Add
Enter L-carnitine, mechanical stirring is uniformly mixed it.500 μm are coated on protective film.Backing film is covered, is compressed, cutting is being carried on the back
Graphene oxide Electric radiant Heating Film is bonded on lining form, aluminium plastic bag is sealed.Application method is the same as embodiment 1.
Percutaneous penetration the result shows that, 24 hours cumulative release amounts of the patch can reach 39.71 μ g/cm2。
3 triamcinolone acetonide acetate of embodiment is dispelled scar transdermal patch
1. drug-reservoir formula:
Triamcinolone acetonide acetate 3g
DURO-TAK 387-2510 medical pressure sensitive adhesive 77g
Glycerol 20g
2. prepared by patch:
DURO-TAK 387-2510 medical pressure sensitive adhesive is added in glycerol, triamcinolone acetonide acetate and (contains acrylate polymer
40.5%, ethyl acetate 54.1%, hexane 5.4%) in, 60 DEG C of temperature constant magnetic stirrings are uniformly mixed, and are made it completely dissolved.It stands
1 hour, bubble removing.It is coated with 600 μm, 90 DEG C of drying 10min on protective film, covers backing film, compresses, cutting, in backing film
Upper bonding graphene oxide Electric radiant Heating Film, aluminium plastic bag are sealed.Application method is the same as embodiment 1.
Percutaneous penetration the result shows that, 24 hours cumulative release amounts of the patch can reach 23.83 μ g/cm2。
4 ascorbic acid whitening transdermal patch of embodiment
1, drug-reservoir formula:
2, prepared by patch:
Acid polyethylene pyrrolidones, polyethylene glycol, propylene glycol, calcium carbonate are added to the water, are uniformly mixed.It is added anti-
Bad hematic acid, mechanical stirring are uniformly mixed it.1mm is coated on protective film.Backing film is covered, is compressed, cutting, on backing film
It is bonded graphene oxide Electric radiant Heating Film, aluminium plastic bag is sealed.Application method is the same as embodiment 1.
Percutaneous penetration the result shows that, 24 hours cumulative release amounts of the patch can reach 28.59 μ g/cm2。
5 DICLOFENAC DIETHYLAMINE rheumatism transdermal patch of embodiment
1, drug-reservoir formula:
2, prepared by patch
DICLOFENAC DIETHYLAMINE is added in ethyl alcohol, sodium lactate is added after mixing, promotes DICLOFENAC DIETHYLAMINE dissolution,
Be added DURO-TAK 87-2677 medical pressure sensitive adhesive, 60 DEG C temperature constant magnetic stirring 1 hour, stand 1 hour removing bubble, be coated on
On protective film, coating thickness is 200 μm, 80 DEG C of drying 15min, covers backing film, is compressed, and cutting is bonded oxygen on backing film
Graphite alkene Electric radiant Heating Film, aluminium plastic bag are sealed.Application method is the same as embodiment 1.
Percutaneous penetration the result shows that, 24 hours cumulative release amounts of the patch can reach 44.48 μ g/cm2。
The crease-resistant transdermal patch of 6 sheep placenta of embodiment
1, drug-reservoir formula:
2, prepared by patch:
Polyvinyl alcohol, Artemisia Glue, sorbierite, zinc oxide, zinc oxide, superfine silica gel powder are added to the water, are uniformly mixed.
Freeze-dried sheep placenta extract powder is added, mechanical stirring is uniformly mixed it.1mm is coated on protective film.Backing film is covered, is compressed, cutting,
Graphene oxide Electric radiant Heating Film is bonded on backing film, aluminium plastic bag is sealed.Application method is the same as embodiment 1.
Percutaneous penetration the result shows that, 24 hours cumulative release amounts of the patch can reach 26.17 μ g/cm2。
Obviously, the above embodiment of the present invention be only to clearly illustrate example of the present invention, and not be pair
The restriction of embodiments of the present invention may be used also on the basis of the above description for those of ordinary skill in the art
To make other variations or changes in different ways, all embodiments can not be exhaustive here, it is all to belong to this hair
The obvious changes or variations that bright technical solution is extended out are still in the scope of protection of the present invention.
Claims (10)
1. a kind of graphene oxide Electric radiant Heating Film transdermal patch, which is characterized in that the graphene oxide Electric radiant Heating Film transdermal patch from
On down successively include: graphene oxide Electric radiant Heating Film, backing film, drug-reservoir and protective film.
2. graphene oxide Electric radiant Heating Film transdermal patch according to claim 1, which is characterized in that the graphene oxide electricity
Hotting mask is heated by being connected to power supply, and operative temperature is 35-50 DEG C；Preferably 40-45 DEG C.
3. graphene oxide Electric radiant Heating Film transdermal patch according to claim 1, which is characterized in that the graphene oxide electricity
Hotting mask is removably bonded on backing film, can be preferably bonded by heat-resisting glue.
4. graphene oxide Electric radiant Heating Film transdermal patch according to claim 1, which is characterized in that the graphene oxide electricity
Hotting mask includes graphene oxide conductive layer and insulating protective layer；Preferably, the material of the insulating protective layer is polyimides, gathers
One or two kinds of mixture in ethylene glycol terephthalate.
5. graphene oxide Electric radiant Heating Film transdermal patch according to claim 4, which is characterized in that the drug-reservoir is water
Gelling agent or pressure-sensitive adhesive.
6. graphene oxide Electric radiant Heating Film transdermal patch according to claim 5, which is characterized in that the original of the hydrogel adhesive
Material includes bulk pharmaceutical chemicals, high-molecular bone frame material, moisturizer, sticky agent, filler.
7. graphene oxide Electric radiant Heating Film transdermal patch according to claim 5, which is characterized in that the pressure-sensitive adhesive
Raw material includes bulk pharmaceutical chemicals, pressure sensitive adhesive and solubilizer.
8. graphene oxide Electric radiant Heating Film transdermal patch according to claim 7, which is characterized in that the pressure sensitive adhesive is propylene
Esters of gallic acid pressure sensitive adhesive or polyisobutene class pressure sensitive adhesive；Preferably, the solubilizer include lactic acid, sodium lactate, boric acid, citric acid,
One or more of mixture in tartaric acid.
9. graphene oxide Electric radiant Heating Film transdermal patch according to claim 6 or 7, which is characterized in that the bulk pharmaceutical chemicals are
Cosmetic actives and drug effective component, including analgesic active principle, fat reducing effective component, scar of dispelling effective component, whitening
One or more of mixture in effective component, rheumatism and antirheumatic.
10. graphene oxide Electric radiant Heating Film transdermal patch according to claim 6 or 7, which is characterized in that oxygen every square centimeter
The content range of bulk pharmaceutical chemicals is 0.2-2mg in graphite alkene Electric radiant Heating Film transdermal patch.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811387114.0A CN109481422B (en) | 2018-11-20 | 2018-11-20 | Graphene oxide electrothermal film transdermal patch |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811387114.0A CN109481422B (en) | 2018-11-20 | 2018-11-20 | Graphene oxide electrothermal film transdermal patch |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109481422A true CN109481422A (en) | 2019-03-19 |
| CN109481422B CN109481422B (en) | 2022-11-11 |
Family
ID=65697146
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811387114.0A Active CN109481422B (en) | 2018-11-20 | 2018-11-20 | Graphene oxide electrothermal film transdermal patch |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109481422B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020207793A1 (en) * | 2019-04-08 | 2020-10-15 | Universite De Lille | Cutaneous device for storing and releasing molecules, and corresponding method |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102000044A (en) * | 2010-11-25 | 2011-04-06 | 沈阳药科大学 | Azasetron transdermal patch and preparation method thereof |
| CN104219797A (en) * | 2014-09-10 | 2014-12-17 | 浙江碳谷上希材料科技有限公司 | Graphene electrothermal film |
| WO2016153272A1 (en) * | 2015-03-23 | 2016-09-29 | 광주과학기술원 | Method for preparing hydrogel containing reduced graphene oxide |
| CN108272774A (en) * | 2018-03-15 | 2018-07-13 | 广西中医药大学 | A kind of graphene treatment dysmenorrhea plaster and preparation method thereof |
| CN108295164A (en) * | 2018-02-10 | 2018-07-20 | 广西中医药大学 | A kind of graphene rheumatoid arthrosis pain patch and preparation method thereof |
| CN108295127A (en) * | 2018-03-14 | 2018-07-20 | 广西中医药大学 | A kind of production method of graphene Electric radiant Heating Film pain-stopping external use patch |
| CN108371688A (en) * | 2018-04-12 | 2018-08-07 | 广西中医药大学 | A kind of graphene analgesic patch and preparation method thereof |
-
2018
- 2018-11-20 CN CN201811387114.0A patent/CN109481422B/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102000044A (en) * | 2010-11-25 | 2011-04-06 | 沈阳药科大学 | Azasetron transdermal patch and preparation method thereof |
| CN104219797A (en) * | 2014-09-10 | 2014-12-17 | 浙江碳谷上希材料科技有限公司 | Graphene electrothermal film |
| WO2016153272A1 (en) * | 2015-03-23 | 2016-09-29 | 광주과학기술원 | Method for preparing hydrogel containing reduced graphene oxide |
| CN108295164A (en) * | 2018-02-10 | 2018-07-20 | 广西中医药大学 | A kind of graphene rheumatoid arthrosis pain patch and preparation method thereof |
| CN108295127A (en) * | 2018-03-14 | 2018-07-20 | 广西中医药大学 | A kind of production method of graphene Electric radiant Heating Film pain-stopping external use patch |
| CN108272774A (en) * | 2018-03-15 | 2018-07-13 | 广西中医药大学 | A kind of graphene treatment dysmenorrhea plaster and preparation method thereof |
| CN108371688A (en) * | 2018-04-12 | 2018-08-07 | 广西中医药大学 | A kind of graphene analgesic patch and preparation method thereof |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020207793A1 (en) * | 2019-04-08 | 2020-10-15 | Universite De Lille | Cutaneous device for storing and releasing molecules, and corresponding method |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109481422B (en) | 2022-11-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Benson et al. | Topical and transdermal drug delivery: from simple potions to smart technologies | |
| Shahzad et al. | Breaching the skin barrier through temperature modulations | |
| Tanner et al. | Delivering drugs by the transdermal route: review and comment | |
| Perumal et al. | Turning theory into practice: the development of modern transdermal drug delivery systems and future trends | |
| JP5542665B2 (en) | Matrix-type transdermal administration agent and method for producing the same | |
| JP2007083091A (en) | Apparatus for administration of transdermal pharmaceuticals | |
| Bala et al. | Transdermal drug delivery system (TDDS)-a multifaceted approach for drug delivery | |
| WO2013126697A1 (en) | Transdermal compositions and methods for treating stretch marks | |
| CN105168189A (en) | Traditional Chinese medicine thermoosmosis pain-relieving paste | |
| JP5350575B2 (en) | Sheet-like pack and method for producing the same | |
| KR100976418B1 (en) | Mask pack using the water-vapor controllable sheet | |
| CN101961418B (en) | Double-controlled release, high-dosage and low-irritation capsaicin compound transdermal patch | |
| Bhowmik et al. | Recent trends in challenges and opportunities in transdermal drug delivery system | |
| CA2473541A1 (en) | Substance delivery device | |
| CN109481422A (en) | A kind of graphene oxide Electric radiant Heating Film transdermal patch | |
| Atkinson et al. | Targets in dermal and transdermal delivery and classification of penetration enhancement methods | |
| JP2018513736A (en) | Electric heatable plaster | |
| CN107468412B (en) | Heating and heating material structure | |
| Sonkar et al. | A review on transdermal patches as a novel drug delivery system | |
| Banu et al. | Approaches and Current Trends of Transdermal Drug Delivery System-A Review | |
| JPH0320217A (en) | Nasal inhalant cataplasm | |
| JP2002104957A (en) | Patch for external use | |
| JPH0749042B2 (en) | Thermal patch | |
| Shankar et al. | Patches: A Novel approach for development of topical drug delivery system | |
| WO2007119467A1 (en) | Percutaneous absorption promoting agent and percutaneous absorption preparation using the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information |
Inventor after: Leng Jing Inventor after: Zhang Suohui Inventor after: Zhao Lichun Inventor after: Wang Baorui Inventor after: Song Ce Inventor after: Feng Guanping Inventor before: Leng Jing |
|
| CB03 | Change of inventor or designer information | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |